Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Name: Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)
Published: 2018
License: Public Domain

National Heart, Lung, and Blood Institute (NHLBI) · 2018

ClinicalTrials.gov · Datasets · License: Public Domain · 2018

Open Source ↗

safety and tolerability, compare shingrix vaccine response rates, chronic lymphocytic leukemia (cll), small lymphocytic lymphoma (sll), ibrutinib, acalabrutinib, shingles, herpes, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Related documents